BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20516573)

  • 1. Designing a low-cost drug resistance database for viral hepatitis.
    Kuiken C
    Antivir Ther; 2010; 15(3 Pt B):517-20. PubMed ID: 20516573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus mutations associated with antiviral therapy.
    Bartholomeusz A; Locarnini S
    J Med Virol; 2006; 78 Suppl 1():S52-5. PubMed ID: 16622878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-resistant viral hepatitis.
    Wright M; Main J; Thomas HC
    J Infect; 2000 Jul; 41(1):1-4. PubMed ID: 10942634
    [No Abstract]   [Full Text] [Related]  

  • 4. Virology of hepatitis B and C viruses and antiviral targets.
    Pawlotsky JM
    J Hepatol; 2006; 44(1 Suppl):S10-3. PubMed ID: 16338022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus escape mutants induced by antiviral therapy.
    Sheldon J; Soriano V
    J Antimicrob Chemother; 2008 Apr; 61(4):766-8. PubMed ID: 18218641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment modalities for hepatitis B viral infection and resistance to antiviral therapy.
    Pai SB; Pai RB; Schinazi RF
    Panminerva Med; 2003 Sep; 45(3):165-73. PubMed ID: 14618114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
    J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conference.
    Buti M
    IDrugs; 2008 Apr; 11(4):239-41. PubMed ID: 18379952
    [No Abstract]   [Full Text] [Related]  

  • 10. Low-abundance drug resistance mutations: extending the HIV paradigm to hepatitis B virus.
    Menzo S; Vincenti D; Solmone M; Prosperi M; Bruselles A; Abbate I; Rozera G; Capobianchi MR
    J Infect Dis; 2009 Dec; 200(11):1798-9; author reply 1799-1800. PubMed ID: 19905934
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment predictors of a sustained virologic response in hepatitis B and C.
    Kau A; Vermehren J; Sarrazin C
    J Hepatol; 2008 Oct; 49(4):634-51. PubMed ID: 18715665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis.
    Motta JS; Mello FC; Lago BV; Perez RM; Gomes SA; Figueiredo FF
    J Gastroenterol Hepatol; 2010 Jan; 25(1):101-6. PubMed ID: 19817965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanisms of drug resistance in hepatitis viruses B and C].
    Yotsuyanagi H; Koike K
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():493-6. PubMed ID: 17455669
    [No Abstract]   [Full Text] [Related]  

  • 14. Viral hepatitis at a crossroad.
    Lok AS; Pawlotsky JM
    Gastroenterology; 2012 May; 142(6):1261-3. PubMed ID: 22537431
    [No Abstract]   [Full Text] [Related]  

  • 15. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
    Sheldon J; Camino N; Rodés B; Bartholomeusz A; Kuiper M; Tacke F; Núñez M; Mauss S; Lutz T; Klausen G; Locarnini S; Soriano V
    Antivir Ther; 2005; 10(6):727-34. PubMed ID: 16218172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B and C viruses: molecular identification and targeted antiviral therapies.
    Berenguer M; Wright TL
    Proc Assoc Am Physicians; 1998; 110(2):98-112. PubMed ID: 9542765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus genetic diversity.
    Echevarría JM; Avellón A
    J Med Virol; 2006; 78 Suppl 1():S36-42. PubMed ID: 16622876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to overcome antiviral-resistant hepatitis B virus?
    Song BC
    Intervirology; 2010; 53(1):29-38. PubMed ID: 20068338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
    Locarnini S; Warner N
    Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coevolution and HBV drug resistance.
    Khudyakov Y
    Antivir Ther; 2010; 15(3 Pt B):505-15. PubMed ID: 20516572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.